Bayerische Motoren Werke ADR (BMWYY)

CarGym, a leader in high-performance aftermarket parts for European luxury vehicles, has expanded its global presence. This move strengthens the company's footprint in international markets, offering premium parts for luxury cars worldwide.

North Vancouver, BC, 24th December 2025, ZEX PR WIRE, In an era where drivers often feel uncertain about where to take their vehicles for trustworthy repairs, Bruno Automotive continues to stand as a pillar of reliability, craftsmanship, and transparency in North Vancouver. Serving the community since 1983, Bruno Automotive has

MIAMI, FL - In an industry where car accidents often lead to logistical chaos, Auto Body Lab is officially setting a new standard for automotive recovery in South Florida. Operating as a premier distributor of comprehensive collision repair and paint services, Auto Body Lab ( https://autobodylab.com/ ) bridges the gap between distressed drivers and elite, certified restoration solutions.

HealthLynked (OTCQB: HLYK) announced a strategic consulting partnership with PBACO Holding LLC, a physician-led, value-based care organization supporting more than 15,000 physicians across 26 states and managing over 400,000 patient lives. The partnership is intended to strengthen HealthLynked’s integration with large insurance payers and accelerate deployment of its AI-enabled care-coordination platform by leveraging PBACO’s expertise in value-based contracting, commercial and government ACO program design, payer relationships, and multi-state provider network operations.

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration.

Oncotelic Therapeutics (OTCQB: OTLC ) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (“SABCS”), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use ( ibn.fm/LxQ7N ).

Immunotherapy, an approach that seeks to stimulate the immune system to attack and destroy cancer cells, is a new field of research that has shown remarkable results in some patients. However, the overall fraction of patients who can benefit from immunotherapy is still very low, and researchers have been looking for ways to make this treatment modality work for a lot more patients.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational therapy, underscoring the potential of SGX302 as a noncarcinogenic, photodynamic treatment.

A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the center of biodefense preparedness as public awareness of ricin’s lethality grows.

Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements.

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition .

In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer.

The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3% . These economics have created a bottleneck that leaves patients waiting years for new treatments that rarely arrive.

The pre-owned vehicle industry in Riverside is experiencing a shift as TM Motors redefines what buyers should expect from their car-purchasing experience. Located at 10100 Arlington Ave., the dealership has built a reputation for prioritizing customer satisfaction over high-pressure sales tactics, creating a welcoming environment for those seeking quality transportation options.

A study that involved an analysis of patient records in New York has discovered that breast cancer, and especially aggressive forms of this cancer, is occurring at a higher rate among younger women aged below 40. This group is currently regarded as low risk for breast cancer by the existing screening guidelines, and this calls for a review of those guidelines.

After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the local level took the hardest hit when compared to federal health officials. As things stand, even state and federal health officials are losing even the little trust that the public still had in them. For a healthcare system to function, public trust is vital because people want to believe that the professionals they entrust with their health have their best interests at heart.

Caring Brands (NASDAQ: CABR) closed its underwritten U.S. public offering of 1,000,000 shares of common stock at $4.00 per share for gross proceeds of about $4 million before underwriting discounts and expenses, completing the Company’s uplisting to the Nasdaq Capital Market, where its shares began trading on Nov. 13, 2025. Caring Brands granted the underwriter a 45-day option to purchase up to 150,000 additional shares and intends to use net proceeds for general working capital, marketing and sales of its proprietary products, and repayment of certain debt.

Since 1991, there has existed a recommendation requiring all newborns to receive a vaccine against Hepatitis B at birth. However, an advisory panel on vaccines voted on Friday to end this recommendation and instead recommended that only babies whose mothers have had a positive test for hepatitis B should receive the shot at birth.

When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant. Soligenix (NASDAQ: SNGX), a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need, recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM) for the treatment of cutaneous T-cell lymphoma, with the overall blinded response rate standing at 48% for patients who have completed treatment ( https://ibn.fm/Ol9Er ).

JAF Executive Travel is a leading luxury chauffeur company based in London, providing first-class transportation across the UK. The company offers tailored travel solutions for airport and cruise port transfers, business travel, private jet connections, major sports and entertainment events, and VIP occasions.

The fight against glioblastoma, a deadly brain cancer, has been boosted by new research conducted at Washington University that has developed nasal drops which can travel through nerves found in the nose and reach different parts of our central nervous system in order to fight the glioblastoma cells there.

A newly published study shows that the fight against cancer could be boosted by considering approaches that seek to disrupt the mechanisms through which tumor cells respond to damage to their DNA. Targeting these pathways could make immunotherapy more effective for a lot more people.

BioMedWire Editorial Coverage : Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) ( profile ), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), where it is currently running the final confirmatory trial necessary before seeking global marketing authorization. As the Trump administration pursues new health-policy measures focused on chronic and rare diseases, Soligenix’s programs are positioned at a pivotal crossroads of scientific innovation and national healthcare goals. The company is working alongside several prominent leaders in the pharmaceutical and life sciences sectors, including AMGEN Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Citius Oncology Inc. (NASDAQ: CTOR) and…